Participated · Equity · Mar 2026

Scinus Group develops the Osilaris platform (formerly the Scinus Cell Expansion system) for scaling up stem cell cultivation using volume-expandable culture bags to enable 3D cultivation at clinical scale. The system is designed for Good Manufacturing Practice (GMP) compliance to help transition therapies from laboratory vials to clinical doses within a single platform. The company emphasizes clinical-scale, volume-expandable 3D growth rather than traditional 2D flask-based methods. Scinus plans to use the recent €3M strategic investment to expand operations and increase R&D efforts. Leadership changes tied to the investment include appointment of Dr. Erik Vossenaar as Executive Director and the addition of CEO Dr. Janeska de Jonge to the Board as a Non-Executive Director. The company was founded by Prof. Dr. Joost de Bruijn, Prof. Dr. Clemens van Blitterswijk, and FrankJan van der Velden.

Participated · Series A · Nov 2022

Enzyre develops an ambulant diagnostic platform that measures up to sixteen coagulation reactions from a small blood sample without laboratory infrastructure. Its first product, Hemophilia EnzyCard, uses the proprietary EnzyPad technology to determine coagulation status in people with hemophilia. The platform is designed for use at home, on the road, or in critical care and can support telemedicine. Reported patient benefits include avoiding crisis situations, empowering patients to optimize treatment, and reducing GP visits. The company raised €12M in a Series A to accelerate development of its proprietary platform and establish manufacturing capabilities. Enzyre is a Nijmegen-based spin-out from Radboud University Medical Center developing Enzypad, a near-patient testing (NPT) device for measuring biomarkers in body fluids. The Enzypad platform uses single-use microfluidic cartridges and requires only a small blood volume, with the ability to measure up to twelve biomarkers simultaneously without laboratory infrastructure. Its first application targets hemophilia, providing real-time coagulation status and automatically sending results to treating physicians via a mobile phone app. Enzyre signed a collaboration with Takeda in December 2019 to develop Enzypad for congenital bleeding disorders, validating the approach. The company positions Enzypad for at-home, on-the-road, and critical-care use and states the technology has broad applicability beyond coagulation testing. Novalis Biotechnology Incubation has joined Enzyre's investor base as part of a recent financing.